<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592393</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2020-2950</org_study_id>
    <nct_id>NCT04592393</nct_id>
  </id_info>
  <brief_title>Pancreas Cancer Surveillance Using an Abbreviated MRI</brief_title>
  <official_title>Clinical Feasibility of Abbreviated MRI for Surveillance in High Risk Group for Developing Pancreas Cancer: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Foundation of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish a prospective cohort of developing pancreas cancer and&#xD;
      surveillance MRI protocol. With the focused surveillance protocol, we perform surveillance&#xD;
      for pancreas cancer for five years to estimate the risk of pancreas cancer and the clinical&#xD;
      feasibility of the surveillance MRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of pancreas cancer</measure>
    <time_frame>1 year after the last surveillance MRI.</time_frame>
    <description>number of detected pancreas cancer (resectable &amp; BRPC only) in surveillance MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scan time of abbreviated PB MRI for surveillance</measure>
    <time_frame>1 month after the first surveillance MRI.</time_frame>
    <description>table time, in-room time measurement for feasibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of pancreas cancer risk</measure>
    <time_frame>1 year after the last surveillance MRI.</time_frame>
    <description>rate of developing pancreas cancer during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of pancreas cancer</measure>
    <time_frame>1 year after the last surveillance MRI.</time_frame>
    <description>number of detected pancreas cancer of all stages (resectable, BRPC, LAPC, metastatic) in surveillance MRI.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of performance of abbreviated PB MRI</measure>
    <time_frame>1 year after the last surveillance MRI.</time_frame>
    <description>comparison of the rates of pancreas cancer detection between abbreviated MRI and conventional follow-up methods (in available cases)</description>
  </other_outcome>
  <other_outcome>
    <measure>Identification of super-high risk group of developing pancreas cancer</measure>
    <time_frame>1 year after the last surveillance MRI.</time_frame>
    <description>Identification of any common radiologic features and gene mutation in participants in whom pancreas cancer develop during the study period.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Abbreviated PB MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short and Focused non-contrast MRI for surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Abbreviated PB MRI</intervention_name>
    <description>Annual non-contrast PB MRI.</description>
    <arm_group_label>Abbreviated PB MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Gene mutation test</intervention_name>
    <description>K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.</description>
    <arm_group_label>Abbreviated PB MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Conventional follow-up</intervention_name>
    <description>Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.</description>
    <arm_group_label>Abbreviated PB MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  On follow-up due to first degree-family history of PAC&#xD;
&#xD;
          -  Or on follow-up for BD-IPMN (&gt;= 2 cm) or main-duct type IPMN (&gt; 5 mm)&#xD;
&#xD;
          -  And signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indication of performing MRI&#xD;
&#xD;
          -  Not satisfying the selection criteria.&#xD;
&#xD;
          -  Previously diagnosed with pancreatic malignancy&#xD;
&#xD;
          -  Pregnancy or planning pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Hee Lee, RN</last_name>
    <phone>82-2-2072-4117</phone>
    <email>redlion55@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong Hee Yoon, MD</last_name>
    <phone>82-2-2072-2584</phone>
    <email>cinamon1@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Hee Lee, RN</last_name>
      <phone>82-2-2072-4177</phone>
      <email>redlion55@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeong Hee Yoon, MD</last_name>
      <phone>82-2-2072-2584</phone>
      <email>cinamon1@snu.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jeong Min Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pancreas cancer</keyword>
  <keyword>intraductal papillary mucinous neoplasm</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

